Sutro Biopharma Presents Data from Dose-Optimization Portion of REFRαME-O1 Trial in Patients with Platinum Resistant Ovarian Cancer at SGO 2025

9 months ago 30
Read Entire Article
  1. Homepage
  2. Finance
  3. Sutro Biopharma Presents Data from Dose-Optimization Portion of REFRαME-O1 Trial in Patients with Platinum Resistant Ovarian Cancer at SGO 2025

Related

Inglis buys American International Group shares worth $1,200

Inglis buys American International Group shares worth $1,200...

24 minutes ago 1
Form PRE 14A 5&2 Studios For: 31 December

Form PRE 14A 5&2 Studios For: 31 December

24 minutes ago 1
NXG NextGen Infrastructure Income Fund announces at-the-market equity offering

NXG NextGen Infrastructure Income Fund announces at-the-mark...

24 minutes ago 1

Trending

1. jalen johnson
2. target nye hours
3. nashville new years
4. uconn vs xavier
5. morgan scalley
6. jalen suggs
7. jay huff
8. is chick fil a open on new year's eve
9. pf changs
10. costco hours

Popular

College football by the odds: Vegas picks and preview of Ohio State vs. Notre Dame

College football by the odds: Vegas picks and preview of Ohi...

11 months ago 651
What is Tren de Aragua, the Venezuelan gang targeted by Trump?

What is Tren de Aragua, the Venezuelan gang targeted by Trum...

9 months ago 516
Taiwan slightly cuts 2025 GDP growth outlook amid Trump tariffs concern

Taiwan slightly cuts 2025 GDP growth outlook amid Trump tari...

10 months ago 382
Australian whose blood saved 2.4 million babies dies

Australian whose blood saved 2.4 million babies dies

9 months ago 338
What to do in Las Vegas this week: January 2-8

What to do in Las Vegas this week: January 2-8

11 months ago 333
English (US) English (US) ·
About Us · Contact Us · Terms & Conditions ·

© Sincity Press 2025. All rights are reserved